At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Total raised: $92M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.10.2024 | Series A | $92M | - |
Mentions in press and media 4
| Date | Title | Description |
| 29.10.2024 | The Surge of Series A Funding: A Look at Kivu Bioscience and Caldera + Lab | In the world of startups, funding is the lifeblood. Recently, two companies have emerged from the shadows, each securing significant Series A funding. Kivu Bioscience and Caldera + Lab are not just chasing dollars; they are on a mission to ... |
| 28.10.2024 | Kivu Bioscience Raises $92M in Series A Funding | Kivu Biosciences, a San Francisco, CA-based biotech company developing antibody-drug conjugates, raised $92M in Series a funding. The round was led by Novo Holdings, with participation from Gimv, Red Tree Venture Capital, HealthCap as well ... |
| 28.10.2024 | Caldera + Lab Raises $6M in Series A Funding | Caldera + Lab, an Austin, TX-based men’s skincare brand, raised $6M in Series A funding. HIPstr, the early-stage investment arm of HighPost Capital, made the investment. The company intends to use the funds to accelerate growth, increase it... |
| - | Kivu Bioscience | “At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.” |